An observational study in Relapse in Schizophrenia, sponsored by AstraZeneca. Completed at 61 sites in Hungary. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-10-24.
Sponsored by AstraZeneca · Observational
The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients
4,279 studies on the registry are indexed under Recurrence; 988 are open to participants now.
This study's enrollment of 1,606 is above the median of 200 across 702 observational studies indexed under Recurrence.
Browse Recurrence studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Psychiatric outpatients
Exclusion Criteria:
Rate of patients remained relapse free after 6 months of treatment
Time frame: on the 60th day of treatment
Rate of patients remained relapse free after 6 months of treatment
Time frame: on the 180th day of treatment
connection between relapse and affective symptoms
Time frame: on the 60th day of treatment
connection between relapse and affective symptoms
Time frame: 180th day of treatment
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca